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Abstract
The standard treatment of brucellar spondylitis with a combination of two antibiotics for 6–12 weeks is associated with high rates of
treatment failure and relapse. The present study aimed to assess the safety and efficacy of a treatment strategy based on the prolonged
administration of a triple combination of suitable antibiotics. Eighteen patients with brucellar spondylitis were treated with a combina-
tion of at least three suitable antibiotics (doxycycline, rifampin, plus intramuscular streptomycin or cotrimoxazole or ciprofloxacin) until
the completion of at least 6 months of treatment, when clinical, radiological and serology re-evaluation was performed. If necessary, the
treatment was continued with additional 6-month cycles, until resolution or significant improvement of clinical and radiological findings,
or for a maximum of 18 months. At presentation, the median age was 66 years (range, 42–85 years) with male predominance. The
median duration of therapy was 48 weeks (range 24–72 weeks). Treatment was discontinued early because of side-effects in only one
patient. Surgical intervention was required for three patients. At the end of treatment all patients had a complete response. After com-
pletion of treatment, all patients were followed up with regular visits. During the follow-up period (duration 1–96 months, median
36.5 months), no relapses were observed. In conclusion, prolonged (at least 6 months) administration of a triple combination of suitable
antibiotics appears to be an effective treatment for brucellar spondylitis.
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Introduction
Brucellar spondylitis might be a devastating complication
because, quite often, it is associated with neurological com-
plications, requires spinal surgery, and results in permanent
functional sequelae [1]. Even though it was described back in
1932 [2], there is still controversy regarding major treatment
issues, such as the optimal antibiotic regimen, the duration
of treatment and the criteria by which to consider the
disease as cured [3]. The reason for this confusion is that
the existing studies comprise small series of cases, treated
and followed very heterogeneously.
In the largest published studies [4–8], various combina-
tions of two antibiotics with known efficacy against Brucella
were administered for 6–12 weeks, with disappointing
results. Alp and coworkers reported that the standard regi-
men (doxycycline combined with streptomycin) for at least
12 weeks remains the first choice [3]. Solera et al treated 35
patients for a median duration of antimicrobial therapy of
120 days, but with high relapse and failure rates (5/35, and 9/
35 respectively) [9]. Nevertheless, all these series and a
recent meta-analysis [10] made clear that failure rates are
much higher when the duration of treatment is 6 weeks or
less than when treatment is continued until 12 weeks
(43.66% vs. 17.43%). Therefore the duration of treatment
suggested by the World Health Organization for acute,
uncomplicated brucellosis (6 weeks) is clearly not sufficient
for patients with spondylitis. Yet, even 12 weeks of treatment
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is not optimal; a recent retrospective study of 96 patients
treated for at least 3 months with suitable combinations of
antibiotics reported treatment failure rate 20%, attributable
mortality 2.6% and 6% of the patients had severe functional
sequelae [7]. On the other hand, there are some small, early
studies, suggesting that a triple combination of suitable antibi-
otics administered for 6–8 weeks achieves more acceptable
cure rates [11,12].
The high failure and relapse rates observed in patients
treated for 6–12 weeks urged three Greek centres to adopt
a different treatment and follow-up strategy for brucellar
spondylitis based on the several principles: the minimum
duration of treatment should be 24 weeks; if there is no
clear resolution of clinical and radiological findings the
treatment should be continued for up to 72 weeks; the
regimen should contain three suitable antibiotics; a complete
clinical, serology and imaging work-up should be performed
every 6 months, to rule out relapse and to assess the need
for further treatment. In the present study, we report the
efficacy of this treatment strategy in 18 consecutive patients
with brucellar spondylitis.
Materials and Methods
Study population and setting
From October 2000 until December 2009, 11 cases of bru-
cellar spondylitis were diagnosed and followed up prospec-
tively at the Laikon General Hospital, Athens; one case at
the General Hospital of Arta, a city in north-western
Greece; and six cases at the General Hospital of Tripolis, a
city which lies in southern Greece; the last hospital serves
an area with a long tradition of sheep farming.
Diagnosis
The diagnosis of brucellosis was established by the clinical
findings compatible with brucellosis, positive standard aggluti-
nation test (SAT, 1:160 or higher) [13], and/or by isolating
Brucella species from blood or bone marrow, other body
fluids, or tissue specimens. An ELISA for Brucella-specific IgM
and IgG serum antibodies, as well as the Coombs test, were
used as additional diagnostic tools where available. In five
cases, computed tomography-guided biopsy of the affected
spinal region was performed.
Demographics and laboratory evaluation
The demographic variables recorded at presentation were
age, sex, occupation, type of exposure to Brucella melitensis,
associated illnesses, clinical presentation and diagnostic delay.
The baseline haematology studies included total and differen-
tial white blood cell counts, haemoglobin levels, erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP) and
biochemistry profile.
Radiographic studies
Diagnosis of spondylitis was confirmed by magnetic reso-
nance imaging (MRI). Findings suggestive of spinal involve-
ment were decreased signal intensity in the vertebral bodies
on T1-weighted images, increased signal in the vertebral
bodies on T2-weighted images, increase in signal in discs
on T2-weighted images, loss of end-plate definition on
T1-weighted images and contrast enhancement in the discs
on T1-weighted images with gadolinium [14].
Definitions
Spondylitis was defined as infection of the intervertebral disk
and the adjacent vertebrae, with or without associated epi-
dural or psoas abscesses [15].
Therapeutic failure was defined as persistent or worsening
symptoms and signs of the disease and increasing MRI
findings, at the completion of 24 weeks of therapy [4]. Partial
remission was considered to have clinical improvement and
stable or improved MRI findings (i.e. no new lesions and
stable or improved initial lesions). Complete remission was
considered as the resolution of all clinical findings (with the
exception of mild residual mechanical pain) and resolution or
significant improvement of radiological findings of spondylitis.
Relapse was defined as the reappearance of symptoms,
new positive blood cultures, and/or worsening imaging
findings during the follow-up, after the discontinuation of
antibiotics [4].
Sequelae were considered to have occurred when pain,
neurological deficits or functional limitation persisted for
longer than 6 months after the end of treatment. The sever-
ity of clinical sequelae was categorized according to the
patient’s functional status: mild sequelae, no neurological
deficits but pain with exercise, not preventing the patients
from performing their usual work or daily activities; moder-
ate sequelae, mild neurological deficits and pain, interfering
with patient’s ability to work; and severe sequelae, perma-
nent pain requiring bed rest and analgesics, and/or motor or
sensorial deficits [4].
Indications for surgery were severe mechanical instability
of the affected spine, treatment failure after 24 weeks of
antibiotic therapy, large paravertebral or epidural abscesses
not responding to medical treatment, cauda equina
syndrome, and severe weakness of muscle as a result of
collapse of the vertebral body [4,9].
Adverse effects that could result in treatment modification
included: hepatotoxicity, defined as a more than five-fold
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increase in aspartate or alanine aminotransferase levels over
the baseline value or more than ten times the upper limit of
the normal range; nephrotoxicity, defined as more than
twice the upper limit of the normal creatinine level range;
ototoxicity; serious skin reactions; and central nervous
system toxicity [16].
Treatment and follow-up
All patients were treated and followed up using the protocol
described on Table 1. In December 2009, all patients were
contacted and re-evaluated by the caring physicians. The
Ethics Committees of the participating hospitals approved
the study protocol and all patients provided their informed
consent.
Results
Baseline characteristics
During the study period, 18 patients (12 were male) with
brucellar spondylitis were diagnosed, treated and followed
up according to our protocol. The median age was 66 years
(range 42–85 years) (Table 2). Four patients had an occu-
pational exposure and all the patients reported ingestion of
unpasteurized dairy products. The vertebral level involved
was lumbar or lumbo-sacral in 11 (61.1%) cases, cervical in
two (11.1%) cases, thoracic in one (5.5%) case, whereas, in
four (22.2%) cases, lumbar and thoracic regions were
affected simultaneously (Table 2). At presentation, all
patients experienced pain, either constant or occasional, of
the affected spinal region.
The time from the onset of symptoms to the diagnosis of
spondylitis was in the range 15–365 days (median 45 days).
For 14 patients (77.7%), the diagnoses of brucellosis and
spinal osteomyelitis were made simultaneously. In four
patients, vertebral involvement was diagnosed 2, 3, 7 and
9 months after the diagnosis of brucellosis, respectively. In
these four patients, standard therapy with two antibiotics
was given prior the diagnosis of spondylitis, for various time
periods.
At presentation, the most common laboratory finding was
elevated ESR (100%) and elevated CRP levels (100%). ESR
was in the range 18–85 mm/h (median 46.5 mm/h). CRP
levels were in the range 1.2–43 mg/L (median, 8.5 mg/L).
Anaemia was found in ten patients (55.5%) and leukocytosis
in four patients. Abnormal liver function tests were found in
seven patients (38.8%), which were attributed to brucellosis.
Standard agglutination testing of initial samples was positive
in 13 (72.2%) of the 18 patients. In the rest of the patients with
negative SAT, computed tomography-guided biopsy of the
TABLE 1. Treatment and follow-up strategy
Week Intervention
0 Diagnosis
External immobilization of the spine
1–3 Doxycycline (per oral, 100 mg twice daily) plus rifampin
(900 mg, per oral once daily) plus streptomycin
(1 g i.m., once daily)
4–24 Doxycycline (per oral, 100 mg twice daily) plus rifampin
(900 mg, per oral once daily) plus sulfamethoxazole– trimethoprim
(800/160 mg, p.o., twice daily)a
4–8–12–16–20 Follow-up visits
Clinical examination
Routine haematology and biochemistry to rule out side-effects
of the treatment
24 Re-evaluation
Clinical
Haematology – biochemistry
Blood culture
Serology
SAT
ELISA
MRI scan of the affected spine
Complete remission Partial remission Treatment failure
Discontinuation of treatment,
follow-up every 6 months for up to 3 years
Clinical
SAT
MRI (every year)
Continuation of treatment until completion of
48 or 72 weeks as needed
Follow-up every 6 months for up to 3 years
Consideration of surgical therapy
Debridement
Diskektomy
Drainage of abscesses
Change of the antibiotic regimen,
according to susceptibility tests,
when available
SAT, standard agglutination test; MRI, magnetic resonance imaging.
aCiprofloxacin (500 mg, per oral, twice daily) was reserved as a second line option in case of discontinuation of rifampin or sulfamethoxazole– trimethoprim.
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affected spinal region was performed. ELISA was performed in
ten patients and revealed high antibody levels in eight patients.
Blood cultures were positive in three patients (16.6%) and all
grew B. melitensis; susceptibility tests were not performed.
All patients underwent an MRI scan at presentation. The
radiological findings [14] were compatible with vertebral
osteomyelitis at the lesion site in all patients. Five patients
had paravertebral masses and four patients had epidural
masses (Table 2).
Treatment
Duration of therapy varied according to clinical, and radiologi-
cal response. The median duration of therapy was 48 weeks
(range 24–72 weeks). Three patients received treatment for
24 weeks (Table 3; patients 4, 8 and 17), eight for 48 weeks
(Table 3; patients 2, 3, 5, 6, 7, 9, 12 and 18) and six for
72 weeks (Table 3; patients 1, 10, 11, 13, 14 and 15). One
patient required treatment discontinuation at approximately
36 weeks because of immune thrombocytopenia (ITP), which
was attributed to the antibiotics (Table 3; patient 16).
Treatment modifications occurred as a result of adverse
effects. Three patients discontinued streptomycin at 2 weeks
and two on the first week because of nephrotoxicity
(Table 3; patients no 1, 2, 4, 5 and 15). Sulfamethoxazole-
trimethoprim was switched to ciprofloxacin because of
adverse effects in three patients (Table 3; patients 7, 8 and
13). In six other patients, there were mild side-effects, such
as gastrointestinal symptoms, mild elevation of liver function
tests or skin reactions. These adverse effects were mild, and
did not require treatment modifications.
Three of the 18 patients underwent surgical intervention
after the initiation of treatment because the spine was
mechanically unstable (Table 3; patients 2, 4 and 6).
Follow-up and outcome
After 24 weeks of treatment, three patients had complete
response with resolution of epidural or paravertebral masses
on MRI (Table 3, patients 4, 8, 17), despite the fact that two
of them continued to have a positive SAT (>1:160). Six
patients of the nine with paravertebral or epidural masses on
MRI initially, showed only slight slight decrease in soft tissue
masses.
Fifteen patients with partial remission received a second
24-week treatment cycle. More specifically, these patients
continued to experience pain of lesser severity at the
affected spinal area with residual imaging findings. At
48 weeks of treatment, eight had complete remission and
discontinued treatment, despite the fact that two patients
continued to have a positive SAT (Table 3, patients 2, 3, 5,
6, 7, 9, 12, 18). Resolution of epidural or paravertebral
masses occurred in three cases who had at the beginning of
treatment. One patient discontinued treatment at 36 weeks
because of ITP, as mentioned above (Table 3, patient 16).
Six patients with residual imaging findings of vertebral oste-
omyelitis and residual symptoms received a third treatment
cycle for total treatment duration of 72 weeks (Table 3,
TABLE 2. Demographics, and baseline clinical, laboratory, and imaging findings among the 18 study patients with brucellar
spondylitis
Patient Sex
Age
(years)
Vertebral
level
affected
Epidural and/or
paravertebral
masses
Findings at diagnosis
Clinical SAT titres MRI
1 Male 67 L5–S1 ()) Constant low back pain, fever 1:5120 +
2 Male 74 L4–L5 ()) Severe lumbar pain, fever 1:2560 +
3 Male 48 C3–C4 ()) Neck pain, night sweats 1:1280 +
4 Female 67 L2–L3 (+) Severe lumbar pain, night sweats <1:160 +
5 Male 85 L2–L3 (+) Lumbar pain, fever <1:160 +
6 Female 61 L2–L3 (+) Severe, constant lumbar pain <1:160 +
7 Male 42 C3–C4 (+) Neck pain <1:160 +
8 Male 67 L3–L4 (+) Lumbar pain, fever, night sweats 1:1200 +
9 Male 65 L5–S1 ()) Low back pain, fever 1:2560 +
10 Female 70 L4–L5 (+) Constant low back pain 1:640 +
11 Male 65 L2–L3 (+) Lumbar pain, fever 1:320 +
12 Male 45 T11–T12
L2–L3
()) Lumbar pain, fever 1:1260 +
13 Female 67 T9–T10 (+) Constant pain, fever 1:640 +
14 Female 64 L2–L3 ()) Lumbar pain <1:160 +
15 Male 76 T6–T7
L4–L5
()) Constant pain, fever 1:5120 +
16 Female 81 L3–L4 ()) Lumbar pain, fever 1:5120 +
17 Male 60 T7–T8
L4–L5
(+) Lumbar pain, fever, night sweats 1:10240 +
18 Male 57 T11–T12
L1–L2
()) Lumbar pain, fever 1:10240 +
MRI+, magnetic resonance imaging findings suggesting active spinal infection; SAT, standard agglutination test.
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patients 1, 10, 11, 13, 14, 15). At the end of treatment all
patients had complete remission of the disease with no resi-
dual paravertebral or epidural masses. However, two patients
continued to have a positive SAT.
After the completion of treatment, all patients were avail-
able for follow-up from 1 up to 96 months (median
36.5 months). During this period, there were no clinical or
radiological relapses. Four patients experienced mild sequa-
lae, consisting of mild pain during heavy exercise or during
weather changes. At the last follow-up, seven patients of the
thirteen with initially high SAT continued to have positive
serology despite clinical and radiological improvement
(Table 3). All patients returned to their previous occupation
and their everyday activities.
Discussion
We report the efficacy of prolonged administration (i.e. at
least 6 months) of suitable antibiotics in a series of 18
consecutive patients with brucellar spondylitis. The median
duration of antimicrobial therapy was 48 weeks (range
24–72 weeks) and the response rate was 100%. No relapses,
mortality or severe sequelae were observed during the long
follow-up period.
There is no agreement for the conservative treatment of
brucellar spondylitis. Issues, such as the optimal antibiotic
regimen, the duration of treatment, the role of surgery and
the follow-up period remain controversial. A recent review
of 8 relevant studies, showed that what matters for the out-
come is the duration of treatment, and not the specific
recommended regimen used [10].
All our patients were treated for at least 24 weeks, but
the majority of them for 48–72 weeks, because the antibiotics
were not discontinued until there was clear improvement of
clinical and radiological findings of active brucellosis. This
strategy resulted in complete remission, in all our patients.
Moreover, at the end of treatment, none had severe func-
tional sequelae, and all returned to their usual occupation.
Three (16.66%) of our patients required surgical treat-
ment, after the initiation of antibiotics, for mechanical insta-
bility; other large series report surgical intervention at rates
ranging from 0% to 30% [4,7–9,17–19]. The major reasons
for surgical intervention in the published series are spinal
instability and treatment failure. None of our patients
required surgery for treatment failure.
Relapses are a significant problem of the treatment of
brucellar spondylodiscitis because they occur at rates ranging
from 0% up to 15% [4,6,7,20,21]. In the present study, none
of the 18 patients who completed therapy relapsed during a
long follow-up period (1–96 months, median 36.5 months).
Relapses usually occur during the first year after infection;
most of our patients (14/18, 77.7%) have been followed up
for more than 1 year, without relapse.
According to a recent position paper, antibiotic regimens
suitable for the treatment of brucellosis include combinations
of doxycycline with rifampicin for 45 days, and doxycycline
for 45 days, plus streptomycin for the initial 2–3 weeks or
gentamicin for the initial 7 days [1]. However, an early study
has shown that the combination doxycycline/streptomycin
may be more effective in brucellar spondylitis [9]. Another
study [11] reported that a triple combination may be more
successful in treating spondylitis compared to standard regi-
mens. However, these studies do not use uniformly accepted
definitions of complete or partial remission, relapse or
sequelae, and patients were not treated or followed up
homogeneously. Our treatment protocol was strict, the clini-
cal criteria for response were clear, and serial MRI scans
were used to make therapeutical decisions.
The major disadvantage of protracted administration of an
antibiotic regimen is the increased risk for adverse effects. In
the present study, eight patients had side-effects requiring
treatment modification and one had a severe side effect (i.e.
ITP) requiring termination of therapy.
The present study has several limitations: there was no
control group because of the rarity of the disease; the small
number of patients does not allow definite conclusions to be
drawn; the response rate of 100% may be attributed to the
protracted duration of treatment or to the triple combination
of antibiotics, or both; there is no comparison with shorter
duration of treatment or another antibiotic regimen; patients
15–18 had follow-up less than 6 months and in these 4 out of
18 patients is difficult to make a proper outcome assessment.
On the other hand, all patients were treated and followed up
homogeneously, the definitions were the same for all partici-
pating centres, and the follow-up period was sufficient to
record possible relapses.
In conclusion, prolonged administration of a three-antibi-
otics combination for at least 6 months seems to comprise
an effective treatment strategy for brucellar spondylitis.
There is clearly a need for multicentre, prospective
therapeutic trials aiming to define the optimal treatment for
spondylitis due to Brucella species.
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